This year’s meeting followed the true and tested script of past AGBT installments. Similarly to last year’s conference, the technological advancements seemed to have slowed and somewhat resulting in no breakthrough announcements, while a larger emphasis was put on the scientific talks. Software analysis announcements related to secondary and tertiary sequence data analysis solutions were almost not present.
Interestingly, the much liked software demo session was mostly reduced to three open source demonstrations and a demonstration of Optalysys, a light-based sequence alignment technology. Too bad, as the software demo part provided a great opportunity to get up to speed with the latest developments across the many commercial solutions Continue reading →
The following is an interview recently conducted by the PMWC Intl. team with Dr. Roger Perlmutter (President, Merck Research Laboratories). The discussion with Dr. Perlmutter focused on various aspects of personalized medicine ranging from key promises to current and future challenges: questions aimed at addressing how personalized medicine will influence the drug discovery process, how the pharmaceutical industry is adjusting and evolving over the next 5-10 years, what big hurdles there are to make personalized medicine a true reality, and – last but not least – how the ongoing pressure on cost control in healthcare vis-à-vis the continuing increase in drug development costs will ultimately shape the fate of personalized medicine and its acceptance by payors, providers, and patients. Continue reading →